We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
25 Jun 2026 - 27 Jun 2026
08 Jul 2026 - 10 Jul 2026

Alliance for Molecular Bladder Cancer Detection

By HospiMedica staff writers
Posted on 02 Jan 2003
An agreement to sublicense exclusive worldwide diagnostic rights to develop and commercialize an immunohistochemistry test to detect the presence of the CD52 antigen in lymph nodes has been announced by Ilex Oncology, Inc. More...
(San Antonio, TX, USA). The licensee is Ventana Medical Systems (Tucson, AZ, USA). The agreement is intended to aid the rapid commercialization of Ilex's cancer drug.

"A standardized test will accelerate the routine screening of the CD52 antigen, which, according to recent findings, appears to be associated with several types of cancer, including lymphomas, in addition to B-cell chronic lymphocytic leukemia (B-CLL). It will also serve as a valuable tool enabling Ilex clinicians to pinpoint cancers in which Campath may play a key therapeutic role.”

Campath (alemtuzumab) is used for the treatment of patients with B-CLL who have been treated with alkylating agents and failed fludarabine therapy. The drug works by targeting the CD52 antigen, resulting in the removal of malignant lymphocytes from the blood, lymph nodes, bone marrow, and other affected organs. Campath is the product of Ilex. Recently, Ilex acquired exclusive commercial rights to CD52 antigen testing from BTG International Limited.





Related Links:
Ilex
Ventana

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Rapid Sepsis Test
SeptiCyte RAPID
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.